Abstract
Dermatomyositis is a systemic autoimmune disease involving both muscle and skin. The presence of a malignancy in a portion of the patients can be detected. The association is usually associated with solid organ tumors but may also be associated with many malignant neoplasms. Thus, it is important not only to carry out disease management in patients, but also to systematically examine them in detail and monitor them in the future. The case to be presented is an example of the relationship that has been mentioned
References
- Madan V, Chinoy H, Griffi ths CE, Cooper RG . Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009;34:451-55.
- Callen JP. Dermatomyositis and malignancy. Clin Rheum Dis 1982;8:369-81.
- Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002;4:415–26.
- Manchul LA, Jin A, Pritchard KI, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 1985;145:1835-9
- Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001;134:1087-95.
- Chinoy H, Cooper RG. Polymyositis and dermatomyositis. In: Watts RA, Conaghan PG, Denton C, Foster H, Isaacs J, MüllerLadner U (eds). Oxford textbook of rheumatology 4th ed. United Kingdom. Oxford University Press; 2013:1009-21.
- Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005;1051:64-71.
Abstract
Dermatomiyozit, hem kas, hem de derinin tutulduğu bir sistemik otoimmün hastalıktır. Hastaların önemli bir kısmında altta bir malignite varlığı tespit edilebilmektedir. Birliktelik genellikle solid organ tümörleri olmakla beraber birçok malign neoplazi ile ilişkili olabilir. Bu nedenle hastalarda sadece hastalık yönetiminin gerçekleştirilmesi değil, sistemik açıdan da detaylı bir şekilde taranması ve gelecekte de bu açıdan izlenmesi önemlidir. Sunulacak olgu bahsettiğimiz birlikteliğe bir örnek teşkil etmektedir
References
- Madan V, Chinoy H, Griffi ths CE, Cooper RG . Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009;34:451-55.
- Callen JP. Dermatomyositis and malignancy. Clin Rheum Dis 1982;8:369-81.
- Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002;4:415–26.
- Manchul LA, Jin A, Pritchard KI, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 1985;145:1835-9
- Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001;134:1087-95.
- Chinoy H, Cooper RG. Polymyositis and dermatomyositis. In: Watts RA, Conaghan PG, Denton C, Foster H, Isaacs J, MüllerLadner U (eds). Oxford textbook of rheumatology 4th ed. United Kingdom. Oxford University Press; 2013:1009-21.
- Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005;1051:64-71.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | October 25, 2019 |
| Submission Date | October 19, 2018 |
| Published in Issue | Year 2019Volume: 58 Suppl: 1 (Rheumatology) |
